Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia

NCT07327255 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Pre-eclampsia

Interventions

DRUG: EG-101

Sponsor

Evergreen Therapeutics, Inc.